Literature DB >> 27040846

Successful treatment with ceritinib after crizotinib induced hepatitis.

Marion Sassier1, Bertrand Mennecier2, Anthony Gschwend2, Mikahl Rein3, Antoine Coquerel4, Xavier Humbert5, Joachim Alexandre4, Sophie Fedrizzi4, Radj Gervais6.   

Abstract

We report two cases of acute hepatitis induced by crizotinib in patients with ALK-rearranged non-small cell lung cancer (NSCLC) who were treated after by a second generation of ALK inhibitor without any incident. These cases suggest that ceritinib could be used as an alternative agent when crizotinib is responsible for hepatitis.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Anaplastic lymphoma kinase (ALK); Ceritinib; Crizotinib; Hepatitis; Non-small-cell-lung-cancer (NSCLC)

Mesh：

Substances：

Year:  2016        PMID： 27040846     DOI： 10.1016/j.lungcan.2016.02.008

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  4 in total

1.  Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report.

Authors:  Yuto Yasuda; Yasuyo Nishikawa; Yuichi Sakamori; Makoto Terao; Kentaro Hashimoto; Tomoko Funazo; Takashi Nomizo; Takahiro Tsuji; Hironori Yoshida; Hiroki Nagai; Hiroaki Ozasa; Toyohiro Hirai; Young Hak Kim
Journal:  Mol Clin Oncol       Date:  2017-06-29

2.  Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma.

Authors:  Takayo Ota; Noriyuki Masuda; Kaoru Matsui; Takao Yamada; Noriko Tanaka; Shunsuke Fujimoto; Masahiro Fukuoka
Journal:  Intern Med       Date:  2019-06-07       Impact factor: 1.271

3.  ALK-positive lung cancer diagnosed with abdominal lymph nodes in a patient receiving hemodialysis.

Authors:  Sung H Song; Ji W Ryu; Hye Y Jwa; Chang W Ha; Hyun Kim; Jae M Jo; Sang H Han
Journal:  Thorac Cancer       Date:  2019-10-07       Impact factor: 3.500

4.  Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC.

Authors:  Ling Peng; Kui Xiao; Jian Cui; Xiang-Hua Ye; Yong-Chang Zhang; Li Mao; Giovanni Selvaggi; Jennifer Yen; Justin Stebbing
Journal:  Onco Targets Ther       Date:  2021-05-25       Impact factor: 4.147
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.